-
1 Comment
Sol-Gel Technologies Ltd is currently in a long term uptrend where the price is trading 15.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.7.
Sol-Gel Technologies Ltd's total revenue sank by 48.8% to $2M since the same quarter in the previous year.
Its net income has increased by 1.7% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 4.1% to $-10M since the same quarter in the previous year.
Based on the above factors, Sol-Gel Technologies Ltd gets an overall score of 4/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | IL0011417206 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | 1.32 |
|---|---|
| PE Ratio | None |
| Target Price | 11.5 |
| Market Cap | 105M |
| Dividend Yield | 0.0% |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SLGL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
